The SH2-SH3 domain-containing adaptor protein CRKL is the predominant tyros
ine phosphorylated protein in chronic myelogenous leukemia (CML) neutrophil
s and BCR-ABL-expressing cell lines. The amino terminal CRKL SH3 domain bin
ds directly to a proline-rich region in the C-terminus of BCR-ABL. BCR-ABL
mutants with deletions of this region were constructed to assess biologic e
ffects of eliminating the CRKL binding site. Yeast two-hybrid analysis and
gel overlay assays show eradication of the direct interaction of CRKL with
BCR-ABL in the proline deletion mutants. However, these BCR-ABL mutants tra
nsform myeloid cells to growth factor independence, and in these cells CRKL
is tyrosine phosphorylated and associates with BCR-ABL. These findings sug
gest both direct and indirect interactions of CRKL, with BCR-ABL. Thus, dis
ruption of the direct interaction with BCR-ABL has not excluded a role for
CRKL in BCR-ABL-mediated transformation.